About eptifibatide
Glycoprotein IIb/IIIa platelet inhibitor
Used for
- Reduces blood-clot complications during acute coronary syndrome treatment
- Prevents clotting during certain coronary angioplasty procedures
Usual adult dose
For acute coronary syndrome: 180 micrograms/kg intravenously, then 2 micrograms/kg/min infusion. For angioplasty, a second 180 micrograms/kg dose is given 10 minutes later. Dosing requires kidney-function adjustment.
Common side effects
- Bleeding
- Low platelet count
- Low blood pressure
- Nausea
Important warnings
- Given only by intravenous infusion under medical supervision
- Bleeding risk increases with other blood thinners or antiplatelet medicines
- Avoid with active bleeding, severe uncontrolled hypertension, or recent major surgery
- Monitor platelet counts and kidney function
Pregnancy
Use only when clearly needed; pregnancy safety information is limited.
Breastfeeding
Breastfeeding safety is not established; clinical assessment is needed.
Interactions
- Anticoagulants such as heparin or warfarin increase bleeding risk
- Other antiplatelet medicines, including aspirin and clopidogrel, increase bleeding risk
- Nonsteroidal anti-inflammatory drugs may increase bleeding risk
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.